Evidence map›Paper›PMID 32793919›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels.

Thomas M Snyder, Rachel M Gittelman, Mark Klinger, Damon H May, Edward J Osborne, Ruth Taniguchi, H Jabran Zahid, Ian M Kaplan, Jennifer N Dines, Matthew T Noakes and 46 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 233 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Shared CD8Nature reviews. Immunology · 2020
    Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

56 authors at 10 institutions in 2 countries.

Thomas M SnyderAdaptive Biotechnologies, Seattle, WA, USA.
Rachel M GittelmanAdaptive Biotechnologies, Seattle, WA, USA.
Mark KlingerAdaptive Biotechnologies, Seattle, WA, USA.
Damon H MayAdaptive Biotechnologies, Seattle, WA, USA.
Edward J OsborneAdaptive Biotechnologies, Seattle, WA, USA.
Ruth TaniguchiAdaptive Biotechnologies, Seattle, WA, USA.
H Jabran ZahidMicrosoft Research, Redmond, WA, USA.
Ian M KaplanAdaptive Biotechnologies, Seattle, WA, USA.
Jennifer N DinesAdaptive Biotechnologies, Seattle, WA, USA.
Matthew T NoakesAdaptive Biotechnologies, Seattle, WA, USA.
Ravi PandyaMicrosoft Research, Redmond, WA, USA.
Xiaoyu ChenAdaptive Biotechnologies, Seattle, WA, USA.
Summer ElasadyAdaptive Biotechnologies, Seattle, WA, USA.
Emily SvejnohaAdaptive Biotechnologies, Seattle, WA, USA.
Peter EbertAdaptive Biotechnologies, Seattle, WA, USA.
Mitchell W PeseskyAdaptive Biotechnologies, Seattle, WA, USA.
Patricia De AlmeidaAdaptive Biotechnologies, Seattle, WA, USA.
Hope O'DonnellAdaptive Biotechnologies, Seattle, WA, USA.
Quinn DeGottardiAdaptive Biotechnologies, Seattle, WA, USA.
Gladys KeitanyAdaptive Biotechnologies, Seattle, WA, USA.
Jennifer LuAdaptive Biotechnologies, Seattle, WA, USA.
Allen VongAdaptive Biotechnologies, Seattle, WA, USA.
Rebecca ElyanowAdaptive Biotechnologies, Seattle, WA, USA.
Paul FieldsAdaptive Biotechnologies, Seattle, WA, USA.
Julia GreisslMicrosoft Research, Redmond, WA, USA.
Lance BaldoAdaptive Biotechnologies, Seattle, WA, USA.
Simona SempriniUnit of Microbiology - The Great Romagna Hub Laboratory, Pievesestina ITALY and DIMES, University of Bologna, Bologna, Italy.
Claudio CerchioneIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Fabio NicoliniImmunotherapy, Cell Therapy and Biobank (ITCB), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy.
Massimiliano MazzaImmunotherapy, Cell Therapy and Biobank (ITCB), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy.
Ottavia M DelmonteImmune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kerry DobbsImmune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Rocio Laguna-GoyaDepartment of Immunology, Hospital 12 de Octubre, i+12, CNIO, Complutense University, Madrid, Spain.
Gonzalo Carreño-TarragonaHematology Department, Hospital 12 de Octubre, i+12, CNIO, Complutense University, Madrid, Spain.
Santiago BarrioHematology Department, Hospital 12 de Octubre, i+12, CNIO, Complutense University, Madrid, Spain.
Luisa ImbertiLaboratorio CREA, Department of Infectious and Tropical Diseases, and Medical Officer, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy.
Alessandra SottiniLaboratorio CREA, Department of Infectious and Tropical Diseases, and Medical Officer, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy.
Eugenia Quiros-RoldanLaboratorio CREA, Department of Infectious and Tropical Diseases, and Medical Officer, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy.
Camillo RossiLaboratorio CREA, Department of Infectious and Tropical Diseases, and Medical Officer, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy.
Andrea BiondiDepartment of Pediatrics and Centro Tettamanti-European Reference Network PaedCan, EuroBloodNet, MetabERN-University of Milano-Bicocca-Fondazione MBBM-Ospedale San Gerardo, Monza, IT.
Laura Rachele BettiniDepartment of Pediatrics and Centro Tettamanti-European Reference Network PaedCan, EuroBloodNet, MetabERN-University of Milano-Bicocca-Fondazione MBBM-Ospedale San Gerardo, Monza, IT.
Mariella D'AngioDepartment of Pediatrics and Centro Tettamanti-European Reference Network PaedCan, EuroBloodNet, MetabERN-University of Milano-Bicocca-Fondazione MBBM-Ospedale San Gerardo, Monza, IT.
Paolo BonfantiDepartment of Infectious Diseases, University of Milano-Bicocca-Ospedale San Gerardo, Monza, IT.
Miranda F TompkinsThe American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Camille AlbaThe American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Clifton DalgardDepartment of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Vittorio SambriUnit of Microbiology - The Great Romagna Hub Laboratory, Pievesestina ITALY and DIMES, University of Bologna, Bologna, Italy.
Giovanni MartinelliIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Jason D GoldmanSwedish Medical Center, Seattle, WA, USA, and Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
James R HeathInstitute for Systems Biology, Seattle, WA, USA.
Helen C SuImmune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Luigi D NotarangeloImmune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Estela Paz-ArtalDepartment of Immunology, Hospital 12 de Octubre, i+12, CNIO, Complutense University, Madrid, Spain.
Joaquin Martinez-LopezHematology Department, Hospital 12 de Octubre, i+12, CNIO, Complutense University, Madrid, Spain.
Jonathan M CarlsonMicrosoft Research, Redmond, WA, USA.
Harlan S RobinsAdaptive Biotechnologies, Seattle, WA, USA.
Adaptive Biotechnologies (United States) · USAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITMicrosoft (United States) · USNational Institutes of Health · USUniversity of Milano-Bicocca · ITUniformed Services University of the Health Sciences · USUniversity of Bologna · ITInstitute for Systems Biology · USUniversity of Washington · US

Funding

Characterization of host immune responses to SARS-CoV-2ZIAAI001270 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NOTARANGELO, LUIGI · 2020 to 2025
$1.2M
6 · The paper itself

Abstract

T cells are involved in the early identification and clearance of viral infections and also support the development of antibodies by B cells. This central role for T cells makes them a desirable target for assessing the immune response to SARS-CoV-2 infection. Here, we combined two high-throughput immune profiling methods to create a quantitative picture of the T-cell response to SARS-CoV-2. First, at the individual level, we deeply characterized 3 acutely infected and 58 recovered COVID-19 subjects by experimentally mapping their CD8 T-cell response through antigen stimulation to 545 Human Leukocyte Antigen (HLA) class I presented viral peptides (class II data in a forthcoming study). Then, at the population level, we performed T-cell repertoire sequencing on 1,815 samples (from 1,521 COVID-19 subjects) as well as 3,500 controls to identify shared "public" T-cell receptors (TCRs) associated with SARS-CoV-2 infection from both CD8 and CD4 T cells. Collectively, our data reveal that CD8 T-cell responses are often driven by a few immunodominant, HLA-restricted epitopes. As expected, the T-cell response to SARS-CoV-2 peaks about one to two weeks after infection and is detectable for at least several months after recovery. As an application of these data, we trained a classifier to diagnose SARS-CoV-2 infection based solely on TCR sequencing from blood samples, and observed, at 99.8% specificity, high early sensitivity soon after diagnosis (Day 3-7 = 85.1% [95% CI = 79.9-89.7]; Day 8-14 = 94.8% [90.7-98.4]) as well as lasting sensitivity after recovery (Day 29+/convalescent = 95.4% [92.1-98.3]). These results demonstrate an approach to reliably assess the adaptive immune response both soon after viral antigenic exposure (before antibodies are typically detectable) as well as at later time points. This blood-based molecular approach to characterizing the cellular immune response has applications in clinical diagnostics as well as in vaccine development and monitoring.

Identifiers

PMID32793919
PMCPMC7418734
OpenAlexW3047483639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.